Cargando…

ARDS infolge schwerer RSV-Infektion Therapeutische Optionen: Therapeutische Optionen

We report on a strikingly frequent referral of former preterm babies with respiratory syncytial virus (RSV) infection and subsequent ARDS in our hospital during the winter 1994/95 with regard to the clinical course under application of alternative treatment modalities. Treatment modalities like inha...

Descripción completa

Detalles Bibliográficos
Autores principales: Varnholt, V., Lasch, P., Suske, G., Koelfen, W., Kachel, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095882/
https://www.ncbi.nlm.nih.gov/pubmed/32226141
http://dx.doi.org/10.1007/s001120050095
_version_ 1783510704443097088
author Varnholt, V.
Lasch, P.
Suske, G.
Koelfen, W.
Kachel, W.
author_facet Varnholt, V.
Lasch, P.
Suske, G.
Koelfen, W.
Kachel, W.
author_sort Varnholt, V.
collection PubMed
description We report on a strikingly frequent referral of former preterm babies with respiratory syncytial virus (RSV) infection and subsequent ARDS in our hospital during the winter 1994/95 with regard to the clinical course under application of alternative treatment modalities. Treatment modalities like inhalational ribavirin, use of bronchodilators and instillation of surfactant had been tried without success. All children (age: 1–43 months) were ventilated for 6.6 (1–17) days with FiO(2) = 1.0 and a mean airway pressure of 16.4 (10–24) cm H(2)O. Mean arterial blood gases were 49 (paO(2)) and 41 (pCO(2)) mm Hg, the OI was 33.4. By inhalational NO in combination with IPPV or HFOV 4 patients could be stabilized, in the other 6 ECMO became necessary. Two of them died in spite of several weeks on ECMO; 8 children survived and could be discharged home after a mean hospital stay of 3 months. Even in very severe cases of RSV infection treatment modalities like NO, HFOV and ECMO can be used successfully. The use of these treatment modalities must be considered before the lung damage is irreversible; in those cases a pre-existing BPD is no contraindication even for extracorporeal lung support.
format Online
Article
Text
id pubmed-7095882
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-70958822020-03-26 ARDS infolge schwerer RSV-Infektion Therapeutische Optionen: Therapeutische Optionen Varnholt, V. Lasch, P. Suske, G. Koelfen, W. Kachel, W. Monatsschr Kinderheilkd Pädiatrische Praxis We report on a strikingly frequent referral of former preterm babies with respiratory syncytial virus (RSV) infection and subsequent ARDS in our hospital during the winter 1994/95 with regard to the clinical course under application of alternative treatment modalities. Treatment modalities like inhalational ribavirin, use of bronchodilators and instillation of surfactant had been tried without success. All children (age: 1–43 months) were ventilated for 6.6 (1–17) days with FiO(2) = 1.0 and a mean airway pressure of 16.4 (10–24) cm H(2)O. Mean arterial blood gases were 49 (paO(2)) and 41 (pCO(2)) mm Hg, the OI was 33.4. By inhalational NO in combination with IPPV or HFOV 4 patients could be stabilized, in the other 6 ECMO became necessary. Two of them died in spite of several weeks on ECMO; 8 children survived and could be discharged home after a mean hospital stay of 3 months. Even in very severe cases of RSV infection treatment modalities like NO, HFOV and ECMO can be used successfully. The use of these treatment modalities must be considered before the lung damage is irreversible; in those cases a pre-existing BPD is no contraindication even for extracorporeal lung support. Springer-Verlag 1996 /pmc/articles/PMC7095882/ /pubmed/32226141 http://dx.doi.org/10.1007/s001120050095 Text en © Springer-Verlag Berlin Heidelberg 1996 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Pädiatrische Praxis
Varnholt, V.
Lasch, P.
Suske, G.
Koelfen, W.
Kachel, W.
ARDS infolge schwerer RSV-Infektion Therapeutische Optionen: Therapeutische Optionen
title ARDS infolge schwerer RSV-Infektion Therapeutische Optionen: Therapeutische Optionen
title_full ARDS infolge schwerer RSV-Infektion Therapeutische Optionen: Therapeutische Optionen
title_fullStr ARDS infolge schwerer RSV-Infektion Therapeutische Optionen: Therapeutische Optionen
title_full_unstemmed ARDS infolge schwerer RSV-Infektion Therapeutische Optionen: Therapeutische Optionen
title_short ARDS infolge schwerer RSV-Infektion Therapeutische Optionen: Therapeutische Optionen
title_sort ards infolge schwerer rsv-infektion therapeutische optionen: therapeutische optionen
topic Pädiatrische Praxis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095882/
https://www.ncbi.nlm.nih.gov/pubmed/32226141
http://dx.doi.org/10.1007/s001120050095
work_keys_str_mv AT varnholtv ardsinfolgeschwererrsvinfektiontherapeutischeoptionentherapeutischeoptionen
AT laschp ardsinfolgeschwererrsvinfektiontherapeutischeoptionentherapeutischeoptionen
AT suskeg ardsinfolgeschwererrsvinfektiontherapeutischeoptionentherapeutischeoptionen
AT koelfenw ardsinfolgeschwererrsvinfektiontherapeutischeoptionentherapeutischeoptionen
AT kachelw ardsinfolgeschwererrsvinfektiontherapeutischeoptionentherapeutischeoptionen